Teduglutide: A Review in Short Bowel Syndrome. Kim E.S. & Keam S.J. 2017. ![Teduglutide: A Review in Short Bowel Syndrome [link]](https://bibbase.org/img/filetypes/link.svg "link")
Paper abstract bibtex Subcutaneous teduglutide (Revestive), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged \textgreater1 year who are stable following a period of postsurgical intestinal adaptation. In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a \textgreater20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo. Improved intestinal absorption and reduced PS requirements were generally maintained in the longer term. Results from a phase III trial in paediatric patients with SBS-IF dependent on PS were consistent with those in adults. Adverse events were mostly of mild to moderate severity and generally consistent with the underlying condition or known mechanism of the drug (e.g. central line-related issues, gastrointestinal events). Teduglutide is therefore a useful treatment option in children (aged \textgreater1 year), adolescents and adults with SBS. Copyright © 2017, Springer International Publishing Switzerland. All Right Reserved.
@misc{kim_e.s._teduglutide:_2017,
title = {Teduglutide: {A} {Review} in {Short} {Bowel} {Syndrome}},
url = {http://rd.springer.com/journal/40265},
abstract = {Subcutaneous teduglutide (Revestive), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged {\textgreater}1 year who are stable following a period of postsurgical intestinal adaptation. In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a {\textgreater}20\% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo. Improved intestinal absorption and reduced PS requirements were generally maintained in the longer term. Results from a phase III trial in paediatric patients with SBS-IF dependent on PS were consistent with those in adults. Adverse events were mostly of mild to moderate severity and generally consistent with the underlying condition or known mechanism of the drug (e.g. central line-related issues, gastrointestinal events). Teduglutide is therefore a useful treatment option in children (aged {\textgreater}1 year), adolescents and adults with SBS. Copyright © 2017, Springer International Publishing Switzerland. All Right Reserved.},
journal = {Drugs},
author = {{Kim E.S.} and {Keam S.J.}},
year = {2017},
keywords = {*short bowel syndrome, *short bowel syndrome/dt [Drug Therapy], *short bowel syndrome/th [Therapy], *teduglutide, *teduglutide/ae [Adverse Drug Reaction], *teduglutide/dt [Drug Therapy], *teduglutide/pd [Pharmacology], *teduglutide/pk [Pharmacokinetics], *teduglutide/sc [Subcutaneous Drug Administration], Child, Parenteral nutrition, abdominal distension/si [Side Effect], acute cholecystitis/si [Side Effect], adolescent, adult, adverse drug reaction, article, catheter infection/co [Complication], central venous catheter, central venous catheter/am [Adverse Device Effect], clinical study, clinical trial, controlled clinical trial, controlled study, decreased appetite/si [Side Effect], disease severity, drug efficacy, drug therapy, drug tolerability, gastrointestinal dysplasia/si [Side Effect], gastrointestinal polyposis/si [Side Effect], gastrointestinal symptom/si [Side Effect], gastrointestinal tract, gastrointestinal tumor/si [Side Effect], human, infant, influenza/si [Side Effect], injection site erythema/si [Side Effect], intestinal failure, intestine absorption, intestine polyp/si [Side Effect], intestine stenosis/si [Side Effect], multicenter study (topic), nonhuman, peripheral edema/si [Side Effect], pharmacodynamic parameters, phase 3 clinical trial, phase 3 clinical trial (topic), placebo, recipient, rectum polyp/si [Side Effect], rhinopharyngitis/si [Side Effect], sepsis/co [Complication], short bowel syndrome/dt [Drug Therapy], side effect, stomach adenoma/si [Side Effect], systematic review, upper abdominal pain/si [Side Effect]}
}
Downloads: 0
{"_id":"2ttzf8Rt6L5d42ZaS","bibbaseid":"kimes-keamsj-teduglutideareviewinshortbowelsyndrome-2017","downloads":0,"creationDate":"2017-05-12T20:20:58.061Z","title":"Teduglutide: A Review in Short Bowel Syndrome","author_short":["Kim E.S.","Keam S.J."],"year":2017,"bibtype":"misc","biburl":"http://bibbase.org/zotero/gxu917","bibdata":{"bibtype":"misc","type":"misc","title":"Teduglutide: A Review in Short Bowel Syndrome","url":"http://rd.springer.com/journal/40265","abstract":"Subcutaneous teduglutide (Revestive), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged \\textgreater1 year who are stable following a period of postsurgical intestinal adaptation. In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a \\textgreater20% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo. Improved intestinal absorption and reduced PS requirements were generally maintained in the longer term. Results from a phase III trial in paediatric patients with SBS-IF dependent on PS were consistent with those in adults. Adverse events were mostly of mild to moderate severity and generally consistent with the underlying condition or known mechanism of the drug (e.g. central line-related issues, gastrointestinal events). Teduglutide is therefore a useful treatment option in children (aged \\textgreater1 year), adolescents and adults with SBS. Copyright © 2017, Springer International Publishing Switzerland. All Right Reserved.","journal":"Drugs","author":[{"firstnames":[],"propositions":[],"lastnames":["Kim E.S."],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["Keam S.J."],"suffixes":[]}],"year":"2017","keywords":"*short bowel syndrome, *short bowel syndrome/dt [Drug Therapy], *short bowel syndrome/th [Therapy], *teduglutide, *teduglutide/ae [Adverse Drug Reaction], *teduglutide/dt [Drug Therapy], *teduglutide/pd [Pharmacology], *teduglutide/pk [Pharmacokinetics], *teduglutide/sc [Subcutaneous Drug Administration], Child, Parenteral nutrition, abdominal distension/si [Side Effect], acute cholecystitis/si [Side Effect], adolescent, adult, adverse drug reaction, article, catheter infection/co [Complication], central venous catheter, central venous catheter/am [Adverse Device Effect], clinical study, clinical trial, controlled clinical trial, controlled study, decreased appetite/si [Side Effect], disease severity, drug efficacy, drug therapy, drug tolerability, gastrointestinal dysplasia/si [Side Effect], gastrointestinal polyposis/si [Side Effect], gastrointestinal symptom/si [Side Effect], gastrointestinal tract, gastrointestinal tumor/si [Side Effect], human, infant, influenza/si [Side Effect], injection site erythema/si [Side Effect], intestinal failure, intestine absorption, intestine polyp/si [Side Effect], intestine stenosis/si [Side Effect], multicenter study (topic), nonhuman, peripheral edema/si [Side Effect], pharmacodynamic parameters, phase 3 clinical trial, phase 3 clinical trial (topic), placebo, recipient, rectum polyp/si [Side Effect], rhinopharyngitis/si [Side Effect], sepsis/co [Complication], short bowel syndrome/dt [Drug Therapy], side effect, stomach adenoma/si [Side Effect], systematic review, upper abdominal pain/si [Side Effect]","bibtex":"@misc{kim_e.s._teduglutide:_2017,\n\ttitle = {Teduglutide: {A} {Review} in {Short} {Bowel} {Syndrome}},\n\turl = {http://rd.springer.com/journal/40265},\n\tabstract = {Subcutaneous teduglutide (Revestive), a glucagon-like peptide-2 analogue that increases intestinal absorption, is approved in the EU for the treatment of short bowel syndrome (SBS) in patients aged {\\textgreater}1 year who are stable following a period of postsurgical intestinal adaptation. In a phase III trial in adults with SBS intestinal failure (IF) dependent on parenteral support (PS), a significantly greater proportion of teduglutide 0.05 mg/kg/day than placebo recipients achieved a {\\textgreater}20\\% reduction in weekly PS volume from baseline to week 20 and maintained it to week 24. The proportion of patients who had a reduction in one or more days on PS was also significant with teduglutide compared with placebo. Improved intestinal absorption and reduced PS requirements were generally maintained in the longer term. Results from a phase III trial in paediatric patients with SBS-IF dependent on PS were consistent with those in adults. Adverse events were mostly of mild to moderate severity and generally consistent with the underlying condition or known mechanism of the drug (e.g. central line-related issues, gastrointestinal events). Teduglutide is therefore a useful treatment option in children (aged {\\textgreater}1 year), adolescents and adults with SBS. Copyright © 2017, Springer International Publishing Switzerland. All Right Reserved.},\n\tjournal = {Drugs},\n\tauthor = {{Kim E.S.} and {Keam S.J.}},\n\tyear = {2017},\n\tkeywords = {*short bowel syndrome, *short bowel syndrome/dt [Drug Therapy], *short bowel syndrome/th [Therapy], *teduglutide, *teduglutide/ae [Adverse Drug Reaction], *teduglutide/dt [Drug Therapy], *teduglutide/pd [Pharmacology], *teduglutide/pk [Pharmacokinetics], *teduglutide/sc [Subcutaneous Drug Administration], Child, Parenteral nutrition, abdominal distension/si [Side Effect], acute cholecystitis/si [Side Effect], adolescent, adult, adverse drug reaction, article, catheter infection/co [Complication], central venous catheter, central venous catheter/am [Adverse Device Effect], clinical study, clinical trial, controlled clinical trial, controlled study, decreased appetite/si [Side Effect], disease severity, drug efficacy, drug therapy, drug tolerability, gastrointestinal dysplasia/si [Side Effect], gastrointestinal polyposis/si [Side Effect], gastrointestinal symptom/si [Side Effect], gastrointestinal tract, gastrointestinal tumor/si [Side Effect], human, infant, influenza/si [Side Effect], injection site erythema/si [Side Effect], intestinal failure, intestine absorption, intestine polyp/si [Side Effect], intestine stenosis/si [Side Effect], multicenter study (topic), nonhuman, peripheral edema/si [Side Effect], pharmacodynamic parameters, phase 3 clinical trial, phase 3 clinical trial (topic), placebo, recipient, rectum polyp/si [Side Effect], rhinopharyngitis/si [Side Effect], sepsis/co [Complication], short bowel syndrome/dt [Drug Therapy], side effect, stomach adenoma/si [Side Effect], systematic review, upper abdominal pain/si [Side Effect]}\n}\n","author_short":["Kim E.S.","Keam S.J."],"key":"kim_e.s._teduglutide:_2017","id":"kim_e.s._teduglutide:_2017","bibbaseid":"kimes-keamsj-teduglutideareviewinshortbowelsyndrome-2017","role":"author","urls":{"Paper":"http://rd.springer.com/journal/40265"},"keyword":["*short bowel syndrome","*short bowel syndrome/dt [Drug Therapy]","*short bowel syndrome/th [Therapy]","*teduglutide","*teduglutide/ae [Adverse Drug Reaction]","*teduglutide/dt [Drug Therapy]","*teduglutide/pd [Pharmacology]","*teduglutide/pk [Pharmacokinetics]","*teduglutide/sc [Subcutaneous Drug Administration]","Child","Parenteral nutrition","abdominal distension/si [Side Effect]","acute cholecystitis/si [Side Effect]","adolescent","adult","adverse drug reaction","article","catheter infection/co [Complication]","central venous catheter","central venous catheter/am [Adverse Device Effect]","clinical study","clinical trial","controlled clinical trial","controlled study","decreased appetite/si [Side Effect]","disease severity","drug efficacy","drug therapy","drug tolerability","gastrointestinal dysplasia/si [Side Effect]","gastrointestinal polyposis/si [Side Effect]","gastrointestinal symptom/si [Side Effect]","gastrointestinal tract","gastrointestinal tumor/si [Side Effect]","human","infant","influenza/si [Side Effect]","injection site erythema/si [Side Effect]","intestinal failure","intestine absorption","intestine polyp/si [Side Effect]","intestine stenosis/si [Side Effect]","multicenter study (topic)","nonhuman","peripheral edema/si [Side Effect]","pharmacodynamic parameters","phase 3 clinical trial","phase 3 clinical trial (topic)","placebo","recipient","rectum polyp/si [Side Effect]","rhinopharyngitis/si [Side Effect]","sepsis/co [Complication]","short bowel syndrome/dt [Drug Therapy]","side effect","stomach adenoma/si [Side Effect]","systematic review","upper abdominal pain/si [Side Effect]"],"downloads":0,"html":""},"search_terms":["teduglutide","review","short","bowel","syndrome","kim e.s.","keam s.j."],"keywords":["*short bowel syndrome","*short bowel syndrome/dt [drug therapy]","*short bowel syndrome/th [therapy]","*teduglutide","*teduglutide/ae [adverse drug reaction]","*teduglutide/dt [drug therapy]","*teduglutide/pd [pharmacology]","*teduglutide/pk [pharmacokinetics]","*teduglutide/sc [subcutaneous drug administration]","child","parenteral nutrition","abdominal distension/si [side effect]","acute cholecystitis/si [side effect]","adolescent","adult","adverse drug reaction","article","catheter infection/co [complication]","central venous catheter","central venous catheter/am [adverse device effect]","clinical study","clinical trial","controlled clinical trial","controlled study","decreased appetite/si [side effect]","disease severity","drug efficacy","drug therapy","drug tolerability","gastrointestinal dysplasia/si [side effect]","gastrointestinal polyposis/si [side effect]","gastrointestinal symptom/si [side effect]","gastrointestinal tract","gastrointestinal tumor/si [side effect]","human","infant","influenza/si [side effect]","injection site erythema/si [side effect]","intestinal failure","intestine absorption","intestine polyp/si [side effect]","intestine stenosis/si [side effect]","multicenter study (topic)","nonhuman","peripheral edema/si [side effect]","pharmacodynamic parameters","phase 3 clinical trial","phase 3 clinical trial (topic)","placebo","recipient","rectum polyp/si [side effect]","rhinopharyngitis/si [side effect]","sepsis/co [complication]","short bowel syndrome/dt [drug therapy]","side effect","stomach adenoma/si [side effect]","systematic review","upper abdominal pain/si [side effect]"],"authorIDs":[],"dataSources":["9LqPNaySNpNxYBFzj"]}